Sanofi — Director's Dealing 2015

Jul 29, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2015-07-27

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-07-27	Common Stock	P	500	$530.7080	Acquired	22859644	Indirect
2015-07-27	Common Stock	P	674	$532.3597	Acquired	22860318	Indirect
2015-07-27	Common Stock	P	823	$533.1927	Acquired	22861141	Indirect
2015-07-27	Common Stock	P	700	$534.3414	Acquired	22861841	Indirect
2015-07-27	Common Stock	P	305	$535.7123	Acquired	22862146	Indirect
2015-07-27	Common Stock	P	1633	$537.1010	Acquired	22863779	Indirect
2015-07-27	Common Stock	P	948	$537.8604	Acquired	22864727	Indirect
2015-07-27	Common Stock	P	1600	$539.2194	Acquired	22866327	Indirect
2015-07-27	Common Stock	P	2503	$540.2032	Acquired	22868830	Indirect
2015-07-27	Common Stock	P	700	$541.1486	Acquired	22869530	Indirect
2015-07-27	Common Stock	P	253	$542.2822	Acquired	22869783	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). The shares were purchased pursuant to a plan intended to comply with Rule 10b5-1(c)(1)(i) under the Exchange Act, entered into with a broker on May 27, 2015.

F3: Purchase prices range from $530.50 to $530.93 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,070,231 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $531.91 to $532.75 per share, inclusive.

F6: Purchase prices range from $532.91 to $533.76 per share, inclusive.

F7: Purchase prices range from $534.07 to $534.82 per share, inclusive.

F8: Purchase prices range from $535.46 to $536.25 per share, inclusive.

F9: Purchase prices range from $536.51 to $537.46 per share, inclusive.

F10: Purchase prices range from $537.58 to $538.37 per share, inclusive.

F11: Purchase prices range from $538.75 to $539.70 per share, inclusive.

F12: Purchase prices range from $539.80 to $540.75 per share, inclusive.

F13: Purchase prices range from $540.84 to $541.75 per share, inclusive.

F14: Purchase prices range from $541.99 to $542.46 per share, inclusive.